Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

AMN Healthcare to Hold First Quarter 2022 Earnings Conference Call on Thursday, May 5, 2022
AMN Healthcare to Hold First Quarter 2022 Earnings Conference Call on Thursday, May 5, 2022


AMN Healthcare Services, Inc. (NYSE: AMN) has scheduled a conference call to discuss its first quarter 2022 financial results and second quarter 2022 outlook on Thursday, May 5, 2022 at 5:00 p.m

Premier, Inc. to Report Fiscal 2022 Third-Quarter Results and Host Conference Call on May 3, 2022: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. to Report Fiscal 2022 Third-Quarter Results and Host Conference Call on May 3, 2022


Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2022 third quarter on Tuesday, May 3, 2022, at approximately 6:30 a.m. ET. The company will also

Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial Carcinoma (MIUC):
Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial Carcinoma (MIUC)


Agilent Technologies Inc. (NYSE: A) today announced CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx immunohistochemical assay to extend the use of the test to patients diagnosed

Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma:
Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma


Agilent Technologies Inc. (NYSE: A) today announced it has expanded CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx as an aid in identifying esophageal squamous cell carcinoma

Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination
Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination


Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ)

Agilent Joins AMBIC to Advance Biomanufacturing:
Agilent Joins AMBIC to Advance Biomanufacturing


Agilent Technologies Inc. (NYSE: A) announced today that it has become a member of the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC). Joining AMBIC demonstrates the company’s

Acadia Healthcare Announces Christopher Hunter as New Chief Executive Officer: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Announces Christopher Hunter as New Chief Executive Officer


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that its Board of Directors has named Christopher Hunter as the Company’s new Chief Executive Officer. He will join Acadia on April

Dexcom Schedules First Quarter 2022 Earnings Release and Conference Call for April 28, 2022 at 4:30 p.m. Eastern Time: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Schedules First Quarter 2022 Earnings Release and Conference Call for April 28, 2022 at 4:30 p.m. Eastern Time


DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2022 financial results after market close on Thursday, April 28, 2022. Management will hold a conference call

AEVIS VICTORIA SA erzielte im Jahr 2021 ein sehr gutes Ergebnis mit ihren Beteiligungen, bei einem Ertrag von CHF 216.4 Millionen und einem Reingewinn von CHF 197.6 Millionen auf Holdingebenehttp://www.aevis.com: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12720/aevis-logo.png
AEVIS VICTORIA SA erzielte im Jahr 2021 ein sehr gutes Ergebnis mit ihren Beteiligungen, bei einem Ertrag von CHF 216.4 Millionen und einem Reingewinn von CHF 197.6 Millionen auf Holdingebene
AEVIS VICTORIA SA erzielte im Jahr 2021 ein sehr gutes Ergebnis mit ihren Beteiligungen, bei einem Ertrag von CHF 216.4 Millionen und einem Reingewinn von CHF 197.6 Millionen auf Holdingebene
AEVIS VICTORIA SA achieved very strong results on its investments in 2021 with a holding income of CHF 216.4 million and a net profit of CHF 197.6 millionhttp://www.aevis.com: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12720/aevis-logo.png
AEVIS VICTORIA SA achieved very strong results on its investments in 2021 with a holding income of CHF 216.4 million and a net profit of CHF 197.6 million
AEVIS VICTORIA SA achieved very strong results on its investments in 2021 with a holding income of CHF 216.4 million and a net profit of CHF 197.6 million
DGAP-AGM: Fresenius SE & Co. KGaA: Announcement  of the Convening of the General Meeting on May 13, 2022 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24693/Fresenius.svg.png
DGAP-AGM: Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting on May 13, 2022 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
DGAP-AGM: Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting on May 13, 2022 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
DGAP-HV: Fresenius SE & Co. KGaA: Bekanntmachung der Einberufung zur Hauptversammlung am 13. Mai 2022 mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24693/Fresenius.svg.png
DGAP-HV: Fresenius SE & Co. KGaA: Bekanntmachung der Einberufung zur Hauptversammlung am 13. Mai 2022 mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
DGAP-HV: Fresenius SE & Co. KGaA: Bekanntmachung der Einberufung zur Hauptversammlung am 13. Mai 2022 mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
Lucid Diagnostics to Participate in the Needham 21st Annual Healthcare Conference
Lucid Diagnostics to Participate in the Needham 21st Annual Healthcare Conference


Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”)

DGAP-HV: Fresenius Medical Care AG & Co. KGaA: Bekanntmachung der Einberufung zur Hauptversammlung am 12.05.2022 in Virtuelle Hauptversammlung ohne physische Präsenz der Aktionäre oder ihrer Bevollmächtigten mit dem Ziel der europaweiten Verbreitung
DGAP-HV: Fresenius Medical Care AG & Co. KGaA: Bekanntmachung der Einberufung zur Hauptversammlung am 12.05.2022 in Virtuelle Hauptversammlung ohne physische Präsenz der Aktionäre oder ihrer Bevollmächtigten mit dem Ziel der europaweiten Verbreitung
DGAP-HV: Fresenius Medical Care AG & Co. KGaA: Bekanntmachung der Einberufung zur Hauptversammlung am 12.05.2022 in Virtuelle Hauptversammlung ohne physische Präsenz der Aktionäre oder ihrer Bevollmächtigten mit dem Ziel der europaweiten Verbreitung
DGAP-AGM: Fresenius Medical Care AG & Co. KGaA: Announcement  of the Convening of the General Meeting in Virtuelle Hauptversammlung ohne physische Präsenz der Aktionäre oder ihrer Bevollmächtigten on 12.05.2022 according to article 121 AktG (German S: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23608/Fresenius_Medical_Care_20xx_logo.svg.png
DGAP-AGM: Fresenius Medical Care AG & Co. KGaA: Announcement of the Convening of the General Meeting in Virtuelle Hauptversammlung ohne physische Präsenz der Aktionäre oder ihrer Bevollmächtigten on 12.05.2022 according to article 121 AktG (German S
DGAP-AGM: Fresenius Medical Care AG & Co. KGaA: Announcement of the Convening of the General Meeting in Virtuelle Hauptversammlung ohne physische Präsenz der Aktionäre oder ihrer Bevollmächtigten on 12.05.2022 according to article 121 AktG (German S
DGAP-News: STRATEC SE: STRATEC ERZIELT IM GESCHÄFTSJAHR 2021 NEUE REKORDWERTE BEI UMSATZ UND ERGEBNIS: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24071/375px-Stratec-Biomedical-Logo.svg.png
DGAP-News: STRATEC SE: STRATEC ERZIELT IM GESCHÄFTSJAHR 2021 NEUE REKORDWERTE BEI UMSATZ UND ERGEBNIS
DGAP-News: STRATEC SE: STRATEC ERZIELT IM GESCHÄFTSJAHR 2021 NEUE REKORDWERTE BEI UMSATZ UND ERGEBNIS
DGAP-News: STRATEC SE: STRATEC GENERATES NEW RECORD SALES AND EARNINGS IN 2021 FINANCIAL YEAR: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24071/375px-Stratec-Biomedical-Logo.svg.png
DGAP-News: STRATEC SE: STRATEC GENERATES NEW RECORD SALES AND EARNINGS IN 2021 FINANCIAL YEAR
DGAP-News: STRATEC SE: STRATEC GENERATES NEW RECORD SALES AND EARNINGS IN 2021 FINANCIAL YEAR
Humana Foundation $5.5 Million Investment Sustains Health Equity Momentum in Targeted Communities: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Foundation $5.5 Million Investment Sustains Health Equity Momentum in Targeted Communities


The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, continued its $5.5 million investment in six communities across the United States to improve greater

Simulations Plus Receives $1.7 Million Grant for BIOLOGXsym™ Macromolecule Safety Software: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Receives $1.7 Million Grant for BIOLOGXsym™ Macromolecule Safety Software


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has received a Phase II

Dexcom Announces Four-for-One Forward Stock Split: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Announces Four-for-One Forward Stock Split


DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today that its Board of Directors has approved a four-for-one

LivaNova to Announce First-Quarter 2022 Results: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Announce First-Quarter 2022 Results


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2022 results on Wednesday, May 4, 2022 at 1 p.m

Simulations Plus Hosts the 2022 Model-Informed Drug Development (MIDD+) Scientific Conference: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Hosts the 2022 Model-Informed Drug Development (MIDD+) Scientific Conference


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, announced record-setting attendance and virtual

PAVmed Subsidiary Lucid Diagnostics Announces Launch of VA EsoGuard® Study
PAVmed Subsidiary Lucid Diagnostics Announces Launch of VA EsoGuard® Study


Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”)

DGAP-News: RHÖN-KLINIKUM AG looks back on successful financial year 2021: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23735/Rhoen-klinikum.svg.png
DGAP-News: RHÖN-KLINIKUM AG looks back on successful financial year 2021
DGAP-News: RHÖN-KLINIKUM AG looks back on successful financial year 2021
DGAP-News: RHÖN-KLINIKUM AG schließt Geschäftsjahr 2021 erfolgreich ab: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23735/Rhoen-klinikum.svg.png
DGAP-News: RHÖN-KLINIKUM AG schließt Geschäftsjahr 2021 erfolgreich ab
DGAP-News: RHÖN-KLINIKUM AG schließt Geschäftsjahr 2021 erfolgreich ab